Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular Biology and Genetics

Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity

Hiroaki Fujii, Manabu Yoshida, Zhu Xue Gong, Toshiharu Matsumoto, Yoshitomo Hamano, Masaharu Fukunaga, Ralph H. Hruban, Edward Gabrielson and Toshikazu Shirai
Hiroaki Fujii
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manabu Yoshida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhu Xue Gong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiharu Matsumoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitomo Hamano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaharu Fukunaga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph H. Hruban
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Gabrielson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshikazu Shirai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Carcinosarcomas of the uterus, ovaries, and fallopian tubes are highly aggressive neoplasms with incompletely understood histogenesis. Although recent immunohistochemical, cell culture, and molecular genetic studies all favor these cancers to be monoclonal in origin, the extent of intratumoral genetic heterogeneity in these tumors with divergent histology has not been reported previously. For this study, we microdissected a total of 172 carcinomatous or sarcomatous foci from 17 gynecological carcinosarcomas and analyzed allelic status with 41 microsatellite markers on chromosomal arms 1p, 1q, 3p, 4q, 5q, 6q, 8p, 9p, 10q, 11p, 11q, 13q, 16q, 17p, 17q, 18q, and 22q. With the exception of a single case with microsatellite instability, we found shared allelic losses and retentions among multiple individually dissected foci of each case, strongly supportive of the concept of a monoclonal origin for these neoplasms. In eight of these cases, we also found heterogeneous patterns of allelic loss at limited numbers of chromosomal loci in either the carcinomatous or sarcomatous components of the neoplasms. These heterogeneous patterns of allelic losses were consistent with either genetic progression or genetic diversion occurring during the clonal evolution of these neoplasms. In two cases, we found the specific patterns of genetic progression to be consistent with sarcomatous components of the neoplasms arising from carcinomatous components. We conclude that most of the gynecological carcinosarcomas have a monoclonal origin, and that genetic progression and diversion parallel the development of divergent phenotypes in these tumors. Because phenotypically divergent areas of the tumors share numerous genetic alterations, this divergence most likely occurs relatively late in the evolution of these tumors.

INTRODUCTION

CSs 3 of the female genital tract are uncommon but clinically highly aggressive neoplasms with biphasic histology of carcinomatous and sarcomatous elements (1, 2, 3) . These neoplasms are usually large and bulky tumors and have often spread beyond the primary organ at the time of initial surgery (3, 4, 5) . Histologically, the carcinomatous components can include endometrioid, clear cell, serous, squamous, or mucinous differentiation, or they may be undifferentiated. Sarcomatous components include homologous (endometrial stromal sarcoma, fibrosarcoma, and leiomyosarcoma) elements and, in up to 50% of cases, heterologous (chondrosarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma) elements.

Because these tumors have an intimate admixture of histologically diverse malignant cells, the histogenesis of CSs has long been a matter of speculation and dispute (2 , 3 , 6 , 7) . Three main hypotheses exist to explain these diverse histological elements. In the“ collision tumor theory,” synchronous biclonal tumors are thought to blend together to form CS histology. In the “composition theory,” the stromal element is thought to be reactive and not neoplastic. This second theory has largely been abandoned because metastatic foci also frequently contain malignant stromal elements as well as malignant epithelial elements. The third, and most favored theory, is the “combination tumor theory,” which postulates that both elements originate from a single stem cell clone. According to this theory, the sarcomatous component arises in a carcinoma through evolution of subclones, and thus the carcinomatous component is the primary determinant of their behavior and prognosis (8 , 9) .

A number of recent cell culture, immunohistochemistry, and molecular genetic studies support the monoclonal nature of these neoplasms. For example, cell lines established from CSs have been shown to differentiate into epithelial, mesenchymal, or both components under various culture conditions (10, 11, 12, 13) . Furthermore, immunohistochemical studies have documented the expression of epithelial markers in the sarcomatous components of a large proportion of cases (13, 14, 15, 16, 17, 18, 19) . More recently, X-chromosomal inactivation assays, p53 mutational analyses, and LOH studies have all shown the carcinomatous and sarcomatous elements to share common genetic alterations (20, 21, 22, 23, 24) .

Although these recent studies provide convincing evidence to support the monoclonal origin of these cancers, genetic diversity corresponding to phenotypic diversity has not been reported previously. It is possible to follow the clonal evolution of cancers with markers to identify LOH. In our previous studies of breast cancer progression, we evaluated LOH on multiple chromosomal regions in multiple individually microdissected foci of ductal carcinoma in situ and found patterns of LOH consistent with genetic progression and heterogeneity superimposed on homogeneous genetic changes (25, 26) . For this study, we have used a similar approach to evaluate the genetic evolution of gynecological CSs. Loss of specific alleles at 17 chromosomal loci suspected to harbor tumor suppressor genes was characterized using microsatellite markers in multiple individually microdissected foci of these cancers, and by comparing LOH patterns, we deduced the likely order of genetic changes in the evolution of individual tumors.

MATERIALS AND METHODS

Tissues.

Cases of gynecological CS were identified in the archival pathology files of Juntendo University and Jikei University, confirmed by review of histopathology and tested for the quality of DNA preservation. Of the 17 cases identified, 12 cases originated in the uterus, 3 cases originated in the ovary, and 2 in the fallopian tube (summarized in Table 1 ⇓ ). Heterologous elements were identified in 14 cases, and the remaining 3 cases contained only homologous elements. Coexsistence of other gynecological tumors was identified in case CS2 (CS in the uterus, endometrioid carcinoma in the bilateral ovaries), case CS9 (CS in the uterus and endometrioid carcinoma in the left ovary), and case CS21 (CS in the left fallopian tube and endometrioid carcinoma in the ovary and the uterus).

View this table:
  • View inline
  • View popup
Table 1

Summary of carcinosarcoma cases and their genetic changes

For each case, location, histology (homologous or heterologous), number of tumor foci dissected, results for microsatellite analysis, and deduced genetic patterns are presented.

Microdissection and DNA Extraction.

Serial 8-μm sections were cut, deparaffinized, stained with H&E, visualized with an inverted microscope, and microdissected using a 26-gauge needle. Three to 34 carcinomatous and sarcomatous foci were individually microdissected from each neoplasm (Fig. 1) ⇓ . In case CS1 and case CS21, metastatic foci were also microdissected. A total of 172 foci were microdissected from the 17 cases. Normal control tissue was also dissected from the adjacent nonmalignant stroma, epithelium, or inflammatory infiltrates. Microdissected tissue was digested overnight at 50°C in buffer containing 0.5% NP40, 50 mm Tris-HCl (pH 8.0), 1 mm EDTA, and 200 μg/ml proteinase K. The lysate was heated at 95°C for 10 min and was stored at −20°C until used directly in PCR reaction.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Representative histology of CS case CS1 showing separately dissected carcinoma and sarcoma foci. T#, dissected foci serially numbered; T1, carcinoma component; T2 and T4, sarcoma component.

Detection of LOH.

PCR reactions contained 1 μl of DNA lysate, 0.4μ m[γ-32p]ATP radiolabeled microsatellite primer, 0.2 mm deoxynucleotide triphosphate, 10 mm Tris-HCl (pH 8.3), 1.5 mm MgCl2, 50 mm KCl, and 0.4 unit of Taq polymerase in a total reaction volume of 10 μl Taq was added to reactions prewarmed to 94°C (hot start PCR), and samples were amplified with 35 cycles of PCR amplification. PCR products were separated on a 5% denaturing polyacrylamide-urea-formamide gel, and LOH was determined by more than a 75% reduction of the intensity in one of the two alleles as compared with those in normal control. When only a portion of the foci dissected from a single CS showed LOH, PCR reactions were repeated in duplicate to confirm the LOH and to exclude spurious PCR reactions. If necessary, microdissection was repeated.

All of the PCR primers for microsatellite markers were purchased from Research Genetics Co., Ltd. (Huntsville, AL). Microsatellite markers were selected to cover commonly deleted chromosomal regions in many of human tumors. The following primers were used: 1p and 1q (D1S500, D1S228, D1S158, and D1S318); 3p (D3S1286 and D3S1293); 4q (D4S424, D4S415, and D4S413); 5q (D5S2072, D5S421, and D5S1956); 6q (D6S264, D6S473, and D6S255); 8p (D8S255, D8S264, and D8S261); 9p (D9S1748 and D9S1749); 10q (D10S221, D10S219, and D10S574); 11p (D11S1324); 11q (D11S29 and Int2); 13q (D13S166 and D13S171); 16q (D16S265, D16S541, and D16S261); 17p (TP53, CHRNB1, and D17S786); 17q (D17S588 and D17S579); 18q (D18S46, D18S55, D18S474, and D18S487); and 22q (D22S270).

RESULTS

One case, CS2, was exceptional in showing novel microsatellite alleles (microsatellite instability). All other tumors showed LOH homogeneously throughout the lesions at one to eight chromosomal loci (Table 1) ⇓ . The highest frequency of homogeneous LOH was seen on 17p (11 cases, 64.7%), followed by 9p (7 cases, 41.2%), 13q (6 cases, 35.3%), 4q (5 cases, 29.4%), 3p, 6q, 8p, and 18q (4 cases, 23.5%), 11q, 16q, 17q, and 22q (3 cases, 17.6%), chromosome 1 and 5q, (2 cases, 11.8%), 11p (1 case, 5.9%), and 10q (0 cases). On average, 3.65 chromosomal arms showed LOH.

In eight of these cases, all tumor foci examined showed identical patterns of loss or retention at all alleles tested. Although each of these tumors had a distinctive bidirectional phenotype, no genetic heterogeneity could be detected.

In contrast to these neoplasms with homogeneous LOH, heterogeneous patterns of LOH were noted among individually microdissected foci in eight cases (cases CS1, CS3, CS4, CS5, CS6, CS18, CS19, and CS21). Heterogeneous LOH occurred with one of the following patterns: (a) identical LOH at some loci (consistent with monoclonal origin) and identical additional alleles lost in both carcinoma foci and sarcoma foci of metastatic tumor (one case, CS1; Fig. 2 ⇓ ); (b) additional LOH consistent with genetic progression in some of the sarcoma foci (one case, CS19; Fig. 3 ⇓ ); (c) additional LOH consistent with genetic progression in some of the carcinoma foci (two cases, CS6 and CS18); (d) differing LOH consistent with genetic diversion in some of the carcinoma and sarcoma foci (two cases, CS4 and CS5); (e) additional LOH consistent with genetic progression from original carcinoma to CS only in metastatic foci (one case, CS21; Fig. 4 ⇓ ); and (f) additional LOH consistent with genetic progression and diversion from original carcinoma to carcinoma/sarcoma foci (one case, CS3; Fig. 5 ⇓ ).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Representative microsatellite amplifications of CS1 and proposed sequence of genetic changes and their phenotypic relationship. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; OV, ovary; LM, lung metastasis; Met, metastasis; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in some of the dissected metastatic CS foci. Embedded Image and Embedded Image : both carcinoma ( Embedded Image and Embedded Image ) and sarcoma ( Embedded Image and Embedded Image ) showing exactly the same genetic alteration. Increasing intensity demonstrate advanced but shared genetic changes in both carcinoma and sarcoma components.

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Representative microsatellite amplifications of CS19 and proposed sequence of genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in some of the dissected sarcoma foci. Embedded Image : both carcinoma ( Embedded Image ) and sarcoma ( Embedded Image ) showing exactly the same genetic alteration; Embedded Image , sarcomatous foci with more advanced genetic changes.

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Representative microsatellite amplifications of CS21 and proposed sequence of genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only in dissected carcinoma/sarcoma foci in the fallopian tube; Ov, ovary; FT, fallopian tube; Ut, uterus. Embedded Image and Embedded Image , carcinomatous foci or subclones with increasing intensity representing accumulation of successive genetic changes; Embedded Image : both carcinoma ( Embedded Image ) and sarcoma ( Embedded Image ) showing exactly the same genetic alteration.

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

Representative microsatellite amplifications of CS3 and proposed sequence of its genetic and phenotypic evolution. N, normal control DNA; T, tumor foci dissected separately; C, carcinomatous foci; S, sarcomatous foci; dot, normal alleles; arrowheads, uniform allelic losses throughout the dissected foci; arrows, heterogeneous allelic losses observed only parts of the dissected carcinoma or sarcoma foci; Embedded Image and Embedded Image , carcinomatous foci or subclones with increasing intensity representing accumulation of successive genetic changes; Embedded Image , Embedded Image , Embedded Image , and Embedded Image , sarcomatous foci with increasing intensity representing accumulation of advanced genetic changes.

In addition to these complex patterns of genetic progression and diversion, one case (CS2) was exceptional in that extensive microsatellite instability of most of the microsatellite markers was noted in both carcinomatous and sarcomatous foci. Although many similar new alleles were identified within carcinoma foci or sarcoma foci independently, only a few of the new alleles were shared between carcinoma and sarcoma foci. This strongly suggested the biclonal nature of the uterine CS lesion in this case. An ovarian endometrioid carcinoma occurring in the same individual did not show any of these allelic changes and thus most likely represents a third primary tumor.

Patterns of chromosomal loss (i.e., homogeneous or heterogeneous) in the different neoplastic components of the CSs are summarized in Fig. 6 ⇓ . Loss of several chromosomal arms (17p, 3p, 4q, 6q, 9p, 13q, and 22q) is relatively homogeneous throughout different regions of the tumors. These homogeneous patterns of LOH suggest that these genetic changes occurred relatively early in the clonal evolution of these neoplasms. Conversely, other chromosomal losses (10q, 11p, 11q, 1p, and 1q) were commonly seen in some but not all areas of the neoplasms. These heterogeneous patterns of LOH suggest that these genetic alterations occurred relatively late in the development of the neoplasms. Notably, LOH of 10q was found in only metastases of two cases. The possibility that inactivation of PTEN or another gene on 10q contributes to metastases of these cancers warrants further investigation.

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Cumulated frequency of particular chromosomal loss according to carcinomatous and sarcomatous foci. □, number of cases with homogenous LOH; Embedded Image , number of cases with heterogeneous LOH in which only part of carcinomatous foci showed LOH; , number of cases with heterogeneous LOH in which only part of sarcomatous foci showed LOH; Embedded Image , number of cases with heterogeneous LOH in which part of both carcinomatous and sarcomatous foci showed LOH; Embedded Image, number of cases with heterogeneous LOH in which only metastatic carcinomatous and sarcomatous foci showed LOH.

DISCUSSION

Although cancers have long been recognized to consist of clonal populations of cells, only recently have some neoplastic lesions have been shown to have genetically heterogeneous elements (25, 26, 27, 28, 29, 30, 31, 32) . In many situations, genetic heterogeneity occurs in tumors that have a relatively homogeneous histological appearance. For example, we recently described substantial genetic heterogeneity in early in situ carcinoma of the breast.

It is reasonable to question whether genetic heterogeneity can account for the phenotypic divergence of CSs, which have been shown previously to originate from a single clone. Since the first description by Virchow (8 , 44) , CSs have been reported in ever-increasing number of locations in the human body, such as gastrointestinal tract, upper aerodigestive tact, lung, breast, and genitourinary tract (8 , 33, 34, 35, 36, 37) . To undertake our study of gynecological CSs, we examined numerous individually microdissected foci of both carcinomatous and sarcomatous cells for LOH using microsatellite markers. Sixteen of the 17 cases we studied showed allelic losses shared by all tumor foci, consistent with a monoclonal origin for these tumors. In eight of the cases, all of the dissected foci shared homogeneous genetic changes in both carcinomatous and sarcomatous areas, and no discordant losses were identified. These findings strongly indicate the totipotential nature of the single tumor clone and hence support the combination theory of CS histogenesis.

In addition to this extensive sharing of chromosomal changes, we also noted evidence for genetic progression or genetic diversion within eight of the tumors. In these tumors, we found LOH of additional chromosomal arms in some of the dissected foci (progression) or differing patterns of LOH of one or more chromosomal arms (diversion). Summarizing the pattern of genetic changes observed in our cases, we hypothesize several possible genetic and phenotypic relationships in the clonal evolution of gynecological CSs as shown in Fig. 7 ⇓ . For each tumor, there appears to be a totipotential clone from which all other portions of the tumor evolve. An original clone of a pure carcinoma can then apparently acquire carcinosarcomatous or sarcomatous phenotype by successive genetic changes (CS3 and CS21). On the other hand, we saw no evidence for tumors in which a sarcoma appeared to give rise to carcinosarcomatous or carcinomatous subclones.

Fig. 7.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 7.

Genetic evolution of CS. Accumulation and diversion of genetic changes in the clonal evolution of gynecological CSs and their relationship with histological/phenotypic diversity is summarized. Embedded Image Embedded Image Embedded Image , and Embedded Image , carcinomatous foci or subclones. Increasing intensity represents accumulation of successive genetic changes; Embedded Image Embedded Image Embedded Image Embedded Image , and sarcomatous foci with increasing intensity representing accumulation of advanced or diverged genetic changes; X, no pathway has been demonstrated. Thus, a sarcoma clone giving rise to carcinoma or CS does not exist. Tumor extension and metastasis are also closely related to genetic progression and diversion.

The prognosis of CSs has been proposed to be related to characteristics of specific histological elements, but there is no agreement concerning which histological elements determine the prognosis of these tumors. Sarcomatous components, and especially the presence of rhabdomyosarcomatous components, have been associated with poor outcome, but a number of studies have also emphasized the carcinomatous component as the primary determinant of prognosis (2 , 4 , 9 , 17 , 38 , 39) . Our data demonstrate both carcinomatous and sarcomatous foci to independently have the ability to acquire advanced genetic changes during the evolution of the tumor. It appears reasonable, therefore, that both components of the tumor should be considered when attempting to assess the malignant potential of a particular tumor.

Overall, the high percentage of loci with LOH in these tumors and the high frequency of genetic heterogeneity among different portions of tumors may be related to the relatively aggressive behavior of these cancers. We found the highest frequency of LOH on 17p, a chromosomal arm that includes the p53 locus, and frequent p53 mutations and overexpression have been reported previously in these neoplasms (19 , 20 , 22, 23, 24 , 40) . Because p53 overexpression and 17p LOH both occur concordantly in sarcomatous and carcinomatous components, we suspect that p53 is affected very early in the development of the majority of these tumors. Somewhat surprisingly, LOH of 10q was only infrequently noted in CSs. This chromosomal arm harbors the recently identified tumor suppressor PTEN, which is frequently mutated in endometrioid carcinoma (41, 42, 43) .

The results of our study raise the possibility that inactivation of PTEN, commonly seen in usual endometrial carcinoma, is a relatively uncommon event in the highly malignant CSs. LOH at the PTEN locus on 10q, when it does occur in CSs, may occur late in the progression of these neoplasms. In contrast, inactivation of p53 (and LOH of 17p) appear to be frequent in the pathogenesis of CSs, similar to what is seen in aggressive serous variants of endometrial adenocarcinoma. The possibility that PTEN and p53 alterations have significantly different prognostic implications in developing gynecological neoplasms warrants further investigation in larger samples of these cancers. Together, these findings suggest that CSs are genetically distinct from the majority of endometrial cancers.

In conclusion, our data support the concept that gynecological CSs are in most cases derived from a single clone. The extensive sharing of many genetic alterations by phenotypically diverse areas of tumors suggests that the phenotypic divergence occurs relatively late in the evolution of the cancers. Furthermore, we have demonstrated genetic heterogeneity to accompany the phenotypic divergence, with patterns of genetic alterations that are consistent with both progression and divergence within individual tumors.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 This work was supported in part by a research grant from the Ministry of Education, Science, Sports and Culture of Japan.

  • ↵2 To whom requests for reprints should be addressed, at Department of Pathology II, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Phone: 03-5802-1039; Fax: 03-3813-3164; E-mail: hfujii{at}med.juntendo.ac.jp

  • ↵3 The abbreviations used are: CS, carcinosarcoma; LOH, loss of heterozygosity.

  • Received May 21, 1999.
  • Accepted October 28, 1999.
  • ©2000 American Association for Cancer Research.

References

  1. ↵
    Gompel S., Silverberg S. G. Pathology in gynecology and obstetrics Ed J. B. Lippincott 3, pp. 249–260. Philadelphia 1985.
  2. ↵
    Silverberg S. G., Major F. J., Blessing J. A., Fetter B., Askin F. B., Liao S-Y., Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: a Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol., 9: 1-19, 1990.
    OpenUrlPubMed
  3. ↵
    Silverberg S. G. Mixed Müllerian tumors. Curr. Top. Pathol., 85: 35-56, 1992.
    OpenUrlPubMed
  4. ↵
    Schweizer W., Demopoulos R., Beller U., Dubin N. Prognostic factors for malignant mixed Müllerian tumors of the uterus. Int. J. Gynecol. Pathol., 9: 129-136, 1990.
    OpenUrlCrossRefPubMed
  5. ↵
    Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T., Zola P., La Face B. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol. Oncol., 67: 70-75, 1997.
    OpenUrlCrossRefPubMed
  6. ↵
    Meyer R. Mischgeschwülste des Uterus die komplizieretern tumoren Henke F. Lubarsch O. eds. . Handbuch der Speziellen Pathologischen Anatomie und Histologie, : 412-415, Julius Springer Berlin 1930.
  7. ↵
    Gorstein F., Anderson T. L. Malignant mixed mesodermal tumors: carcinoma, sarcoma or both?. Hum. Pathol., 22: 207-209, 1991.
    OpenUrlCrossRefPubMed
  8. ↵
    Wick M. R., Swanson P. E. Carcinosarcomas. Current perspectives and historical review of nosological concepts. Semin. Diagn. Pathol., 10: 118-127, 1993.
    OpenUrlPubMed
  9. ↵
    Colombi R. P. Sarcomatoid carcinomas of the female genital tract (malignant mixed Müllerian tumors). Semin. Diagn. Pathol., 10: 169-175, 1993.
    OpenUrlPubMed
  10. ↵
    Masuda A., Takeda A., Fukami H., Yamada C., Matsuyama M. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer (Phila.), 60: 2696-2703, 1987.
    OpenUrlCrossRefPubMed
  11. ↵
    Emoto M., Iwasaki H., Kikuchi M., Ishiguro M., Kubota T., Izumi H., Shirakawa K., Kaneko Y. Two cell lines established from mixed Müllerian tumors of the uterus. Morphologic, immunocytochemical, and cytogenetic analyses. Cancer (Phila.), 69: 1759-1768, 1992.
    OpenUrlCrossRefPubMed
  12. ↵
    Emoto M., Iwasaki H., Kikuchi M., Shirakawa K. Characteristics of cloned cells of mixed Müllerian tumor of the human uterus. Cancer (Phila.), 71: 3065-3075, 1993.
    OpenUrlCrossRefPubMed
  13. ↵
    Gorai I., Doi C., Minaguchi H. Establishment and characterization of carcinosarcoma cell line of the human uterus. Cancer (Phila.), 71: 775-786, 1993.
    OpenUrlCrossRefPubMed
  14. ↵
    Bitterman P., Chun B., Kurman R. J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus: a clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol., 14: 317-328, 1990.
    OpenUrlPubMed
  15. ↵
    Meis J. M., Lawrence W. D. The immunohistochemical profile of malignant mixed Müllerian tumor. Overlap with endometrial adenocarcinoma. Am. J. Clin. Pathol., 94: 1-7, 1990.
    OpenUrlPubMed
  16. ↵
    Costa M. J., Khan R., Judd R. Carcinosarcoma (malignant mixed Müllerian [mesodermal] tumor) of the uterus and ovary. Arch. Pathol. Lab. Med., 115: 583-590, 1991.
    OpenUrlPubMed
  17. ↵
    George E., Manivel J. C., Dehner L. P., Wick M. R. Malignant mixed Müllerian tumors: an immunohistochemical study of 47 cases with histogenetic considerations and clinical correlation. Hum. Pathol., 22: 215-223, 1991.
    OpenUrlCrossRefPubMed
  18. ↵
    De Brito P. A., Silverberg S. G., Orenstein J. M. Carcinosarcoma (malignant mixed Müllerian [mesodermal] tumor)of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum. Pathol., 24: 132-142, 1993.
    OpenUrlCrossRefPubMed
  19. ↵
    Mayall F., Rutty K., Campbell F., Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology, 24: 211-214, 1994.
    OpenUrlPubMed
  20. ↵
    Costa M. J., Vogelsang J., Young L. J. T. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed Müllerian tumors): a clinicopathologic study of 74 cases. Mod. Pathol., 7: 619-627, 1994.
    OpenUrlPubMed
  21. ↵
    Thompson L., Chang B., Barsky S. H. Monoclonal origins of malignant mixed tumors (carcinosarcomas): evidence for a divergent histogenesis. Am. J. Surg. Pathol., 20: 277-285, 1996.
    OpenUrlCrossRefPubMed
  22. ↵
    Abeln E. C. A., Smit V. T. H. B. M., Wessels J. W., De Leeuw W. J. F., Cornelisse C. J., Fleuren G. J. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumors. J. Pathol., 183: 424-431, 1997.
    OpenUrlCrossRefPubMed
  23. ↵
    Wada H., Enomoto T., Fujita M., Yoshino K., Nakashima R., Kurachi H., Haba T., Wakasa K., Shroyer K. R., Tsujimoto M., Hongyo T., Nomura T., Murata Y. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res., 57: 5379-5385, 1997.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Knounelis S., Jones M. W., Papadaki H., Bakker A., Swalsky P., Finkelstein S. D. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum. Pathol., 29: 82-87, 1998.
    OpenUrlCrossRefPubMed
  25. ↵
    Fujii H., Marsh C., Cairns P., Sidransky D., Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res., 56: 1493-1497, 1996.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Fujii H., Szumel R., Marsh C., Zhou W., Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res., 56: 5260-5265, 1996.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Boland, C. R., Sato, J., Appelman, H. D., Bresalier, R. S., and Feinberg, A. P. Microallelotyping defines the sequence and tempo of allelic losses at tumor suppressor gene loci during colorectal cancer progression. Nat. Med., 1: 902–909.
  28. ↵
    Shibata D., Navidi W., Salovaara R., Li Z-H., Aaltonen L. A. Somatic microsatellite mutations as molecular tumor clocks. Nat. Med., 2: 676-681, 1996.
    OpenUrlCrossRefPubMed
  29. ↵
    Fujii H., Inagaki M., Kasai S., Miyokawa N., Tokusashi Y., Gabrielson E., Hruban R. H. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol., 151: 1447-1454, 1997.
    OpenUrlPubMed
  30. ↵
    Macintosh C. A., Stower M., Reid N., Maitland N. J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res., 58: 23-28, 1998.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Jovanovic A. S., Boynton K. A., Mutter G. L. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res., 15: 1917-1921, 1996.
    OpenUrl
  32. ↵
    Mutter G. L., Boynton K. A., Faquin W. C., Ruiz R. E., Jovanovic A. S. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res., 56: 4483-4486, 1996.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Weidner N., Zekan P. Carcinosarcoma of the colon. Report of a unique case with light and immunohistochemical studies. Cancer (Phila.), 58: 1126-1130, 1986.
    OpenUrlCrossRefPubMed
  34. ↵
    Santeusanio G., Pascal R. R., Bisceglia M., Costantino A. M., Bosman C. Metaplastic breast carcinoma with epithelial phenotype of pseudosarcomatous components. Arch. Pathol. Lab. Med., 112: 82-85, 1988.
    OpenUrlPubMed
  35. ↵
    Pitts W. C., Rojas V. A., Gaffey M. J., Rouse R. V., Esteban J., Frierson H. F., Kempson R. L., Weiss L. M. Carcinomas with metaplasia and sarcomas of the breast. Am. J. Clin. Pathol., 95: 623-632, 1991.
    OpenUrlPubMed
  36. ↵
    Ro J. Y., Ayala A. G., Sella A., Samuels M. L., Swanson D. A. Sarcomatoid renal cell carcinoma: clinicopathologic study of 42 cases. Cancer (Phila.), 59: 516-526, 1987.
    OpenUrlCrossRefPubMed
  37. ↵
    Young R. H. Carcinosarcoma of the urinary bladder. Cancer (Phila.), 59: 1333-1339, 1987.
    OpenUrlCrossRefPubMed
  38. ↵
    Sreenan J. J., Hart W. R. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am. J. Surg. Pathol., 19: 666-674, 1995.
    OpenUrlPubMed
  39. ↵
    Mascasaet M. A., Waxman M., Fruchter R. G., Boyce J., Hong P., Nicastri A. D., Remy J. C. Prognostic factors in malignant mesodermal (Müllerian) mixed tumors of the uterus. Gynecol. Oncol., 20: 32-42, 1985.
    OpenUrlCrossRefPubMed
  40. ↵
    Liu F-S., Kohler M. F., Marks J. R., Bast R. C., Jr., Boyd J., Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gynecol., 83: 118-124, 1994.
    OpenUrlPubMed
  41. ↵
    Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S. H., Giovanella B. C., Ittmann M., Tycko B., Hibshoosh H., Wingler M. H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Tashiro H., Blazes M. S., Wu R., Cho K. R., Bose S., Wang S. I., Li J., Parsons R., Ellenson L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res., 57: 3935-3940, 1997.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Risinger J. I., Hayes A. K., Berchuck A., Barrett J. C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res., 57: 4736-4738, 1997.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Virchow, R. Die Krankhaften gerschwuste, Vol. 2, pp. 181–182. Berlin, Germany: Hischward, 1869.
PreviousNext
Back to top
January 2000
Volume 60, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity
Hiroaki Fujii, Manabu Yoshida, Zhu Xue Gong, Toshiharu Matsumoto, Yoshitomo Hamano, Masaharu Fukunaga, Ralph H. Hruban, Edward Gabrielson and Toshikazu Shirai
Cancer Res January 1 2000 (60) (1) 114-120;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity
Hiroaki Fujii, Manabu Yoshida, Zhu Xue Gong, Toshiharu Matsumoto, Yoshitomo Hamano, Masaharu Fukunaga, Ralph H. Hruban, Edward Gabrielson and Toshikazu Shirai
Cancer Res January 1 2000 (60) (1) 114-120;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines
  • Identification of Interleukin 8 as an Inhibitor of Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in the Ovarian Carcinoma Cell Line OVCAR3
  • FUS/ERG Gene Fusions in Ewing’s Tumors
Show more Molecular Biology and Genetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement